Lilly Announces Details of Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Lilly announced this. present new data from the Jaypirka (pirtobrutinib) study at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.which will take place December 7-10 in San Diego. Jaipircha is non-covalent and reversible inhibitor of Bruton’s tyrosine kinase (BTK)used in the treatment of hematological neoplasms such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This drug has raised expectations in the medical community as it is the first BTK inhibitor of its type to offer a therapeutic alternative to patients who have already received other BTK inhibitor treatments.

During the event, Lilly will highlight Results from the Phase 3 BRUIN CLL-321 study. This study compares the efficacy of Jaypirka with idelalisib plus rituximab (IdelaR) and bendamustine plus rituximab (BR) regimens. in patients with CLL or LLP who have already been treated with other BTK inhibitors

. Jaypirka achieved the primary objectives of this study, which marks an important milestone as the first randomized phase 3 trial specifically examining a population previously treated with BTK inhibitors. Lilly plans to update data from this study beginning in August 2024, and initial results appear promising for expanding therapeutic options in these patients.

Analysis of Jaipirchi at ASH

In addition to the results of the BRUIN CLL-321 study, Lilly will present more Jaypirchi research at ASH. Among them Survival studies of patients with CLL and LLP treated with different treatment sequenceswhich can provide valuable information about the effects of drug combinations on the progression of these diseases. Also in one of the poster presentations Lilly will share preclinical data on a new bispecific antibody targeting the B-cell activating factor (BAFF) receptor-RxCD3. This antibody is the first of its kind and is being studied as a potential treatment for B-cell malignancies.

Jaypircha is distinguished by its high selectivity for the BTK enzymebeing 300 times more selective than other similar drugs, which played a fundamental role in its development as a therapeutic option. BTK is a key protein in the development of various types of B-cell leukemias and lymphomas. In January 2023, the FDA approved Jaipirka.

for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of therapy, including another BTK inhibitor. Its use is also approved for patients with CLL or NLP who have received at least two lines of treatment, including BTK and BCL-2 inhibitors, and may continue subject to confirmatory studies.

Side effects when using Jaypirka

Although Jaypirca represents a significant advance in the treatment of these neoplasms, its use carries safety risks that clinicians and patients must consider. Serious side effects reported include: severe infections such as pneumonia, sepsis and febrile neutropenia.. Pneumocystis jirovecii pneumonia has also been reported in some patients, highlighting need to constantly monitor for signs of infection and, in special cases, consider the use of antimicrobial prophylaxis. There were similar cases serious and fatal bleedingespecially in the gastrointestinal tract and central nervous system. Lilly recommended assessing the risk-benefit ratio of combining Jaipirka with antithrombotic drugs and adjusting the dose or discontinuing treatment depending on the severity of symptoms.

Studies have shown that in addition to infections and bleeding JP associated with cytopenias (reduction of blood cells), cardiac arrhythmias and the risk of developing new primary malignancies. Patients receiving treatment should also be alert for possible hepatotoxicity and embryofetal toxicity, which requires frequent monitoring of liver parameters. For patients with severe renal impairment, Jaipirka dosages should be adjusted to reduce potential side effects.

---

You may also be interested…